Tadashi Terui
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.
Journal: Dermatology and therapy
Published: October 01, 2025
Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Study.
Journal: Journal of psoriasis and psoriatic arthritis
Published: August 18, 2025
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 14, 2025
Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 23, 2024
Palmoplantar Pustulosis as an Immune-Mediated Inflammatory Disease with a Possible Relevance of Th17 Cell Plasticity: A Narrative Review.
Journal: Dermatology and therapy
Published: November 07, 2024
Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study.
Journal: The Journal of dermatology
Published: November 05, 2024
Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'".
Journal: American journal of clinical dermatology
Published: September 12, 2024
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.
Journal: American journal of clinical dermatology
Published: June 10, 2024
Spesolimab, the first-in-class anti-IL-36R antibody: From bench to clinic.
Journal: The Journal of dermatology
Published: May 13, 2024
International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council.
Journal: JAMA dermatology
Published: May 01, 2024
Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
Journal: Dermatology and therapy
Published: April 02, 2024
Last Updated: 09/26/2026